Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2018-05-15 Capital/Financing Update
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THERANEXUS PUBLIE SA POSITION DE TRESORERIE AU 31 MARS 2018
Capital/Financing Update Classification · 99% confidence The document is titled "THERANEXUS PUBLIE SA POSITION DE TRESORERIE AU 31 MARS 2018" (Theranexus Publishes its Cash Position as of March 31, 2018). It explicitly reports key financial figures (cash position) for a specific interim period (Q1 2018, ending March 31). This content aligns perfectly with the definition of an Interim / Quarterly Report (IR), which covers financial reports for periods shorter than a year. Although it is a brief announcement, it contains the core financial data (cash balance) rather than just announcing that a full report is available, distinguishing it from an RPA. It is not a full Annual Report (10-K) or a standalone Audit Report (AR).
2018-05-15 French
Theranexus presentation at the International Connexins Symposium (Vancouver 14-15 May 2018)
Investor Presentation Classification · 90% confidence The document is an announcement dated May 7, 2018, stating that the company's CSO will make a presentation at an upcoming International Connexins Symposium on May 15th. It details the topic of the presentation and provides background information on the company's research and drug candidates. This content is typical of a press release informing investors and the public about participation in a scientific conference or symposium, which is generally classified as an Investor Presentation (IP) if it's the presentation material itself, or a general announcement. Since this document is the *announcement* of the presentation, and it focuses heavily on scientific/investor-relevant updates, it aligns best with the Investor Presentation (IP) category, as it serves to inform the investment community about ongoing scientific engagement and progress, even though it's not the presentation slides themselves. However, given the options, it is a specific announcement about an event where company information will be shared. It is not a formal regulatory filing (10-K, IR, ER, etc.). It is most closely related to the content shared in an Investor Presentation (IP) or a general press release. Given the context of presenting scientific findings to an audience, 'Investor Presentation' (IP) is the most fitting category for the *subject matter* being announced, even if this specific text is the announcement of that presentation. If a dedicated 'Press Release' category existed, it would fit there, but among the provided codes, IP captures the essence of sharing detailed company/science updates with the market.
2018-05-07 English
Présentation de THERANEXUS au Symposium international sur les connexines (Vancouver 14-15 mai 2018)
Regulatory Filings Classification · 92% confidence The document is a press release dated May 7, 2018, announcing that the Chief Scientific Officer of THERANEXUS will be giving a presentation at an international symposium on connexins in Vancouver on May 14-15, 2018. It details the topic of the presentation and provides background information on the company's technology and pipeline. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about participation in an external scientific event, which falls under general investor relations communication. Since it is an announcement about scientific/investor-facing material (a presentation/conference participation) rather than the presentation itself (which would be an IP or LTR/RNS if it were a legal update), and it doesn't fit the other specific categories, the most appropriate classification is a general Regulatory Filing (RNS) as a catch-all for non-standard corporate communications, or potentially Investor Presentation (IP) if the content strongly resembled a presentation summary, but given the format is a press release announcing the event, RNS is safer, or potentially LTR if it were considered a legal/proceedings update, but it is not. Given the context of sharing scientific updates with the market, and lacking a better fit for a simple announcement of a presentation at a third-party symposium, RNS (Regulatory Filings / Miscellaneous Announcement) is the best fit among the provided options, as it is a general corporate communication.
2018-05-07 French
ORAL PRESENTATION OF THERANEXUS AT THE 9TH EUROPEAN CONGRESS ON NARCOLEPSY 5 AND 6 MAY IN MONTPELLIER
Regulatory Filings Classification · 95% confidence The document is a press release dated May 2, 2018, announcing that Theranexus will be delivering an 'ORAL PRESENTATION' at the '9TH EUROPEAN CONGRESS ON NARCOLEPSY'. It details the speaker, title, date, and location of this presentation. This content directly relates to materials shared or presented at a scientific or investor meeting, which aligns best with the 'AGM Information' category (AGM-R), even though this is a scientific congress presentation rather than a formal Annual General Meeting. Given the options, 'AGM-R' is the closest fit for presentation materials shared at a formal gathering, or alternatively, 'IP' (Investor Presentation) if it were a formal investor deck, but the context is a scientific congress presentation announcement. Since the core subject is the presentation itself being delivered at a congress, and 'AGM-R' covers presentations at general meetings, I will select AGM-R as the best fit for presentation materials, although 'IP' is also plausible if interpreted broadly as 'Investor Presentation'. However, the structure strongly suggests an announcement about an upcoming presentation at a conference, which is often grouped with AGM materials in databases that lack a specific 'Conference Presentation Announcement' code. Given the strict definitions, 'AGM-R' covers presentations at meetings. If this were a formal investor presentation deck, 'IP' would be better. Since it's an announcement of an oral presentation at a medical congress, and no other category fits well, I will lean towards the category covering meeting presentations.
2018-05-02 English
PRÉSENTATION ORALE DE THERANEXUS LORS DU 9ÈME CONGRÈS EUROPÉEN SUR LA NARCOLEPSIE LES 5 ET 6 MAI À MONTPELLIER
AGM Information Classification · 95% confidence The document is titled "PRÉSENTATION ORALE DE THERANEXUS LORS DU 9ÈME CONGRÈS EUROPÉEN SUR LA NARCOLEPSIE" and details the presentation topic, speaker (Medical Director), date, and location of an oral presentation at a scientific congress. This content directly relates to materials shared or presented at an Annual General Meeting (AGM) or similar formal gathering where company updates are delivered to stakeholders, although this specific event is a scientific congress, the nature of the material (presentation slides/summary) aligns best with the 'AGM Information' category, which covers presentations and materials shared during such events. It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS). Given the context of presenting scientific/clinical advances, AGM-R is the most appropriate fit among the provided options for presentation materials.
2018-05-02 French
MISE À DISPOSITION DU DOCUMENT DE RÉFÉRENCE 2017
Report Publication Announcement Classification · 99% confidence The document is titled "MISE À DISPOSITION DU DOCUMENT DE RÉFÉRENCE 2017" (Availability of the 2017 Reference Document) and explicitly states that the 'Document de référence 2017' (Reference Document 2017) has been registered with the AMF (Autorité des marchés financiers). It further mentions that this reference document incorporates the 'rapport financier annuel 2017' (2017 annual financial report), the report on internal controls, and the auditor's fees statement. Since the document's primary function is to announce the availability of a comprehensive annual filing (the Reference Document, which contains the annual report), and the text length is relatively short (2553 chars), it fits the definition of a Report Publication Announcement (RPA). It is announcing the publication of the annual report and related documents, rather than being the full report itself.
2018-04-27 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.